PureTech Health is to develop a combination of a microbiome treatment with checkpoint inhibitor immunotherapy to enhance the effect of the cancer drugs.
Roche’s Tecentriq has been added to the new-look Cancer Drugs Fund for bladder cancer patients, making it the latest in a recent flurry of drugs to be put on the managed access fund.
AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL).
